• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Second Generation Direct-Antivirals for HCV in the Real World


Clinical trials of second generation direct-acting antivirals in HCV show high cure rates. But do those rates reflect real life?

What are HCV cure rates with second-generation direct-acting antivirals in difficult-to-treat populations, such as those with liver transplant or HIV coinfection?


1. Afdhal N, Zeuzem S, Kwo P, et al.; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. NEJM. 2014;370:1889-1898.2.Kowdley KV, Gordon SC, Reddy KR, et al.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. NEJM. 2014;370:1879-88.3. Afdhal N, Reddy KR, Nelson DR, et al.; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. NEJM. 2014;370:1483-1493.4. Ferenci P, Bernstein D, Lalezari J, et al. PEARL-III Study; PEARL-IV Study. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. NEJM. 2014;370:1983-19895. Aspinall AI, Shaheen AA, Kochaksaraei GS, et al. Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients. CMAJ Open. 2018 Jan 5;6(1):E12-E18. doi: 10.9778/cmajo.20170059.

Related Content
© 2024 MJH Life Sciences

All rights reserved.